Abstract
Cardiovascular diseases (CVD) account for nearly half of all deaths in Europe and almost 30% of global deaths. Despite the improved clinical management, cardiovascular mortality is predicted to rise in the next decades due to the increasing impact of aging, obesity, and diabetes. The goal of emerging cardiovascular nanomedicine is to reduce the burden of CVD using nanoscale medical products and devices. However, the development of novel multicom-ponent nano-sized products poses multiple technical, ethical, and regulatory challenges, which often obstruct their road to successful approval and use in clinical practice. This review discusses the rational design of nanoparticles, including safety considerations and regulatory issues, and highlights the steps needed to achieve efficient clinical translation of promising nanomedicinal products for cardiovascular applications.
| Original language | English |
|---|---|
| Pages (from-to) | 1714-1727 |
| Number of pages | 14 |
| Journal | Cardiovascular Research |
| Volume | 114 |
| Issue number | 13 |
| Early online date | 27 Aug 2018 |
| DOIs | |
| Publication status | Published - 1 Nov 2018 |
Fingerprint
Keywords
- Cardiovascular nanomedicine
- Clinical translation
- Nanoparticle design
- Nanosafety
- Regulatory issues
Cite this
}
From design to the clinic : Practical guidelines for translating cardiovascular nanomedicine. / Cicha, Iwona (Corresponding Author); Chauvierre, Cédric; Texier, Isabelle; Cabella, Claudia; Metselaar, Josbert M.; Szebeni, János; Dézsi, László; Alexiou, Christoph; Rouzet, François; Storm, Gert; Stroes, Erik; Bruce, Donald; MacRitchie, Neil; Maffia, Pasquale; Letourneur, Didier.
In: Cardiovascular Research, Vol. 114, No. 13, 01.11.2018, p. 1714-1727.Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - From design to the clinic
T2 - Practical guidelines for translating cardiovascular nanomedicine
AU - Cicha, Iwona
AU - Chauvierre, Cédric
AU - Texier, Isabelle
AU - Cabella, Claudia
AU - Metselaar, Josbert M.
AU - Szebeni, János
AU - Dézsi, László
AU - Alexiou, Christoph
AU - Rouzet, François
AU - Storm, Gert
AU - Stroes, Erik
AU - Bruce, Donald
AU - MacRitchie, Neil
AU - Maffia, Pasquale
AU - Letourneur, Didier
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Cardiovascular diseases (CVD) account for nearly half of all deaths in Europe and almost 30% of global deaths. Despite the improved clinical management, cardiovascular mortality is predicted to rise in the next decades due to the increasing impact of aging, obesity, and diabetes. The goal of emerging cardiovascular nanomedicine is to reduce the burden of CVD using nanoscale medical products and devices. However, the development of novel multicom-ponent nano-sized products poses multiple technical, ethical, and regulatory challenges, which often obstruct their road to successful approval and use in clinical practice. This review discusses the rational design of nanoparticles, including safety considerations and regulatory issues, and highlights the steps needed to achieve efficient clinical translation of promising nanomedicinal products for cardiovascular applications.
AB - Cardiovascular diseases (CVD) account for nearly half of all deaths in Europe and almost 30% of global deaths. Despite the improved clinical management, cardiovascular mortality is predicted to rise in the next decades due to the increasing impact of aging, obesity, and diabetes. The goal of emerging cardiovascular nanomedicine is to reduce the burden of CVD using nanoscale medical products and devices. However, the development of novel multicom-ponent nano-sized products poses multiple technical, ethical, and regulatory challenges, which often obstruct their road to successful approval and use in clinical practice. This review discusses the rational design of nanoparticles, including safety considerations and regulatory issues, and highlights the steps needed to achieve efficient clinical translation of promising nanomedicinal products for cardiovascular applications.
KW - Cardiovascular nanomedicine
KW - Clinical translation
KW - Nanoparticle design
KW - Nanosafety
KW - Regulatory issues
UR - http://www.scopus.com/inward/record.url?scp=85055207494&partnerID=8YFLogxK
U2 - 10.1093/cvr/cvy219
DO - 10.1093/cvr/cvy219
M3 - Review article
VL - 114
SP - 1714
EP - 1727
JO - Cardiovascular Research
JF - Cardiovascular Research
SN - 0008-6363
IS - 13
ER -